A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo.

Vermersch, Patrick; Radue, Ernst-Wilhelm; Putzki, Norman; Ritter, Shannon; Merschhemke, Martin; Freedman, Mark S

Vermersch, Patrick; Radue, Ernst-Wilhelm; Putzki, Norman; Ritter, Shannon; Merschhemke, Martin; Freedman, Mark S.

Afiliación

Vermersch P; University of Lille, CHU Lille, LIRIC - INSERM U995, FHU Imminent, France.
Radue EW; Medical Image Analysis Center, University Hospital Basel, Switzerland.
Putzki N; Novartis Pharmaceuticals Corporation, USA.
Ritter S; Novartis Pharmaceuticals Corporation, USA.
Merschhemke M; Novartis Pharma AG, Switzerland.
Freedman MS; University of Ottawa, The Ottawa Hospital Research Institute, Canada.

Mult Scler J Exp Transl Clin ; 3(3): 2055217317730096, 2017.

Article en En | MEDLINE | ID: mdl-28989795

Palabras clave

Fingolimod; discontinuation; multiple sclerosis; rebound; safety

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Mult Scler J Exp Transl Clin Año: 2017 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google